Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anixa Biosciences IncITUS · Entity 6698 | Director · President & CEO | June 02, 2017 | June 05, 2017 |
| enVVeno Medical CorpNVNO · Entity 8104 | Director · Chief Executive Officer | December 16, 2025 | December 18, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anixa Biosciences Inc
Report date June 02, 2017 · Filed June 05, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 61,553 |
Ending reported balance
After 2017-06-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-06-02 · Purchase · Acquired 100 · Balance 51,653 Row 2 · 2017-06-02 · Purchase · Acquired 9,900 · Balance 61,553 |
enVVeno Medical Corp
Report date December 16, 2025 · Filed December 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2031-11-30 | Direct | 0 |
Reported balance
After 2025-12-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-16 · Other · Disposed 200,000 · Balance 0 F1: The restricted stock units were issued to the Reporting Person on November 30, 2021 pursuant to the Issuer's Amended and Restated 2016 Omnibus Incentive Plan and the Restricted Stock Unit Agreement, subject to vesting upon the achievement of specified performance milestones. The applicable milestones were not achieved, and accordingly, the Reporting Person has agreed to voluntarily surrender and cancel the unvested Restricted Stock Units. |
| Common StockSEC Table I · non-derivative | Direct | 22,236 |
Reported balance
Holding disclosure · report date 2025-12-16 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 22,236 |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units were issued to the Reporting Person on November 30, 2021 pursuant to the Issuer's Amended and Restated 2016 Omnibus Incentive Plan and the Restricted Stock Unit Agreement, subject to vesting upon the achievement of specified performance milestones. The applicable milestones were not achieved, and accordingly, the Reporting Person has agreed to voluntarily surrender and cancel the unvested Restricted Stock Units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 16, 2025 Filed Dec 18, 2025 18:24 UTC | enVVeno Medical Corp NVNO · Entity 8104 | OtherRestricted Stock Units · Derivative | 200,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-028396 · ownership.xml · derivative · entry 2 BERMAN ROBERT ANDREW · CIK 0001258360 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2031-11-30 F1 · derivative.exercise_date: The restricted stock units were issued to the Reporting Person on November 30, 2021 pursuant to the Issuer's Amended and Restated 2016 Omnibus Incentive Plan and the Restricted Stock Unit Agreement, subject to vesting upon the achievement of specified performance milestones. The applicable milestones were not achieved, and accordingly, the Reporting Person has agreed to voluntarily surrender and cancel the unvested Restricted Stock Units. Read SEC document |
| December 19, 2024 Filed Dec 19, 2024 21:51 UTC | enVVeno Medical Corp NVNO · Entity 8104 | PurchaseCommon Stock | 12,000 | $2.55 | $30,600.00 |
DisclosureSEC source: 0001493152-24-050865 · ownership.xml · nonDerivative · entry 1 BERMAN ROBERT ANDREW · CIK 0001258360 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 222,236 Read SEC document |
| December 18, 2024 Filed Dec 20, 2024 20:33 UTC | enVVeno Medical Corp NVNO · Entity 8104 | GrantStock Options · Derivative | 200,000 | $0.00 Strike: $2.57 | $0.00 |
DisclosureSEC source: 0001493152-24-051146 · ownership.xml · derivative · entry 1 BERMAN ROBERT ANDREW · CIK 0001258360 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2034-12-18 F1 · derivative.exercise_date: The common stock options were issued to the Reporting Person on December 18, 2024 pursuant to the Issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended (the "Plan"). The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the three calendar years through 2027. Read SEC document |
| December 05, 2023 Filed Dec 7, 2023 17:05 UTC | enVVeno Medical Corp NVNO · Entity 8104 | GrantStock Options · Derivative | 300,000 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001493152-23-044055 · ownership.xml · derivative · entry 1 BERMAN ROBERT ANDREW · CIK 0001258360 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2033-12-05 F1 · derivative.exercise_date: The common stock options were issued to the Reporting Person on December 5, 2023 pursuant to the Plan. The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the three calendar years through 2026. Read SEC document |
| June 27, 2022 Filed Jun 28, 2022 16:05 UTC | enVVeno Medical Corp NVNO · Entity 8104 | PurchaseCommon Stock | 2,500 | $3.80 | $9,500.00 |
DisclosureSEC source: 0001493152-22-017957 · ownership.xml · nonDerivative · entry 1 BERMAN ROBERT ANDREW · CIK 0001258360 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,236 Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 18:27 UTC | enVVeno Medical Corp NVNO · Entity 8104 | GrantStock Options · Derivative | 349,781 | $0.00 Strike: $6.70 | $0.00 |
DisclosureSEC source: 0001493152-21-030335 · ownership.xml · derivative · entry 2 BERMAN ROBERT ANDREW · CIK 0001258360 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,781 Underlying: Common Stock · 349,781 shares Expires 2031-11-30 F2 · derivative.exercise_date: The common stock options were issued to the Reporting Person on November 30, 2021 pursuant to the Plan. The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the three calendar years through 2024. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 18:27 UTC | enVVeno Medical Corp NVNO · Entity 8104 | GrantCommon Stock | 200,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-21-030335 · ownership.xml · nonDerivative · entry 1 BERMAN ROBERT ANDREW · CIK 0001258360 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,736 F1 · price: The Reporting Person was granted 200,000 restricted stock units on November 30, 2021 pursuant to the issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended (the "Plan"). The restricted stock units are subject to milestone-based vesting as follows: (i) 50% upon SAVVE (Surgical Anti-reflux Venous Valve Endoprosthesis) endpoints being achieved, and (ii) 50% upon the Pre-Market Approval of the VenoValve. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 17:27 UTC | enVVeno Medical Corp NVNO · Entity 8104 | PurchaseCommon Stock | 2,000 | $7.43 | $14,860.00 |
DisclosureSEC source: 0001493152-21-029430 · ownership.xml · nonDerivative · entry 1 BERMAN ROBERT ANDREW · CIK 0001258360 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,736 Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 16:24 UTC | enVVeno Medical Corp NVNO · Entity 8104 | PurchaseCommon Stock | 2,000 | $7.87 | $15,740.00 |
DisclosureSEC source: 0001493152-21-029229 · ownership.xml · nonDerivative · entry 1 BERMAN ROBERT ANDREW · CIK 0001258360 · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,736 Read SEC document |
| May 18, 2021 Filed May 19, 2021 20:20 UTC | enVVeno Medical Corp HJLI · Entity 8104 | PurchaseCommon Stock, $0.00001 par value | 3,000 | $5.47 | $16,410.00 |
DisclosureSEC source: 0001493152-21-012298 · ownership.xml · nonDerivative · entry 1 BERMAN ROBERT ANDREW · CIK 0001258360 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,736 F1 · shares: The reporting person acquired these shares of common stock on the open market. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 21:56 UTC | enVVeno Medical Corp HJLI · Entity 8104 | GrantStock Option · Derivative | 838,000 | $0.00 Strike: $8.20 | $0.00 |
DisclosureSEC source: 0001493152-21-004530 · ownership.xml · derivative · entry 1 BERMAN ROBERT ANDREW · CIK 0001258360 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 838,000 Underlying: Common Stock · 838,000 shares Expires 2031-02-18 F1 · security: The stock option was granted pursuant to the registrant's Amended and Restated 2016 Omnibus Incentive Plan, as amended (the "Plan"). F2 · derivative.exercise_date: The stock options vest in equal quarterly installments over a two a year period, however the stock options may only become exercisable following receipt by the registrant of stockholder approval to increase the size of the Plan sufficiently to permit the exercise in full of such stock options under the Plan. If the registrant's stockholders do not approve an increase in the size of the Plan, the options will be void. Read SEC document |
| July 18, 2020 Filed Jul 21, 2020 21:55 UTC | enVVeno Medical Corp HJLI · Entity 8104 | GrantStock Option · Derivative | 1,080,207 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001493152-20-013751 · ownership.xml · derivative · entry 2 BERMAN ROBERT ANDREW · CIK 0001258360 · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,080,207 Underlying: Common Stock · 1,080,207 shares Expires 2030-07-18 F2 · derivative.exercise_date: The common stock options were issued, and vested upon grant. Read SEC document |
| July 18, 2020 Filed Jul 21, 2020 21:55 UTC | enVVeno Medical Corp HJLI · Entity 8104 | OtherStock Option · Derivative | 1,080,207 | $0.00 Strike: $4.99 | $0.00 |
DisclosureSEC source: 0001493152-20-013751 · ownership.xml · derivative · entry 1 BERMAN ROBERT ANDREW · CIK 0001258360 · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,080,207 shares Expires 2028-04-26 F1 · kind: The Board terminated the common stock options pursuant to Section 17.15 of the Amended and Restated 2016 Omnibus Incentive Plan. Read SEC document |
| July 18, 2020 Filed Jul 21, 2020 21:55 UTC | enVVeno Medical Corp HJLI · Entity 8104 | GrantStock Option · Derivative | 1,000,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001493152-20-013748 · ownership.xml · derivative · entry 1 BERMAN ROBERT ANDREW · CIK 0001258360 · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 100,000 shares Expires 2030-07-18 F1 · derivative.exercise_date: The common stock options were issued to the Reporting Person on July 18, 2020. The award is subject to time-based vesting and will vest in equal monthly portions over three years. Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 18:52 UTC | enVVeno Medical Corp HJLI · Entity 8104 | PurchaseCommon Stock | 21,740 | $1.15 | $25,001.00 |
DisclosureSEC source: 0001493152-19-003384 · ownership.xml · nonDerivative · entry 1 BERMAN ROBERT ANDREW · CIK 0001258360 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,740 F1 · security: The reporting person purchased the shares of common stock in the Registrant's private placement transaction that closed on March 12, 2019. Read SEC document |
| March 12, 2019 Filed Apr 17, 2019 18:47 UTC Amendment | enVVeno Medical Corp HJLI · Entity 8104 | PurchaseCommon Stock | 18,382 | $1.36 | $24,999.52 |
DisclosureSEC source: 0001493152-19-005579 · ownership.xml · nonDerivative · entry 1 BERMAN ROBERT ANDREW · CIK 0001258360 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,382 F1 · security: The reporting person purchased the shares of common stock in the Registrant's private placement transaction that closed on March 12, 2019. F2 · security: The reporting person's original Form 4 included the incorrect number of shares purchased in the private placement and the incorrect price per share paid by the reporting person in the private placement. Read SEC document |
| September 24, 2018 Filed Sep 26, 2018 15:25 UTC | enVVeno Medical Corp HJLI · Entity 8104 | GrantStock Option (Right to Buy) · Derivative | 1,080,207 | $2.71 Strike: $4.99 | $2,927,360.97 |
DisclosureSEC source: 0001493152-18-013747 · ownership.xml · derivative · entry 1 BERMAN ROBERT ANDREW · CIK 0001258360 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,080,207 Underlying: Common Stock · 1,080,207 shares Expires 2028-09-24 F1 · derivative.exercise_date: On September 24, 2018, the Board of Directors of the Company approved the grant of a ten-year option to purchase an aggregate of 1,080,207 shares of the Company's common stock at an exercise price of $4.99 per share (the "Option") to the reporting person, which Option was issued pursuant to the terms of that certain employment agreement, dated March 30, 2018 (the "Effective Date"), between the reporting person and the Company (the "Employment Agreement"). The grant of the Option was in fulfillment of the express terms of the previously agreed to Employment Agreement, which was filed as an exhibit to the Company's Form S-1/A with the Securities and Exchange Commission on April 16, 2018. F2 · derivative.exercise_date: The Employment Agreement provides that the reporting person is entitled to receive an equity grant of an option to purchase up to 6.5% of the Company's common stock outstanding on a fully diluted basis at the closing of the Company's initial public offering. The shares subject to the Option will vest over a period of 2 years, with 1/5th of the shares subject to the Option having vested on the Effective Date (the "Initial Vesting") and the remaining shares vesting in substantially equal monthly installments during the twenty-four (24) month period following the Effective Date and ending March 30, 2020 (as of the date of this report 396,076 shares subject to the Option, including the Initial Vesting, have vested). Read SEC document |
| June 02, 2017 Filed Jun 5, 2017 10:52 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | PurchaseCommon Stock | 9,900 | $0.88 | $8,712.00 |
DisclosureSEC source: 0001513162-17-000183 · primary_doc.xml · nonDerivative · entry 2 BERMAN ROBERT ANDREW · CIK 0001258360 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,553 Read SEC document |
| June 02, 2017 Filed Jun 5, 2017 10:52 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | PurchaseCommon Stock | 100 | $0.85 | $85.00 |
DisclosureSEC source: 0001513162-17-000183 · primary_doc.xml · nonDerivative · entry 1 BERMAN ROBERT ANDREW · CIK 0001258360 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,653 Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 19:56 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | OtherSubscription Right · Derivative | 5,995 | $0.00 Strike: $2.38 | $0.00 |
DisclosureSEC source: 0001513162-17-000104 · primary_doc.xml · derivative · entry 2 BERMAN ROBERT ANDREW · CIK 0001258360 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,995 shares Expires not disclosed F1 · security: ITUS Corporation distributed to holders of its common stock and certain warrants, non-transferrable subscription rights to purchase one share of common stock for each share of common stock held on March 1, 2017. The rights offering expired on March 24, 2017, but the company did not close the rights offering until April 3, 2017. F1 · derivative.expiration_date: ITUS Corporation distributed to holders of its common stock and certain warrants, non-transferrable subscription rights to purchase one share of common stock for each share of common stock held on March 1, 2017. The rights offering expired on March 24, 2017, but the company did not close the rights offering until April 3, 2017. Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 19:56 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | OtherCommon Stock | 5,995 | $2.38 | $14,268.10 |
DisclosureSEC source: 0001513162-17-000104 · primary_doc.xml · nonDerivative · entry 1 BERMAN ROBERT ANDREW · CIK 0001258360 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,553 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.